Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data

• Váldodahkkit: Svetlana Garafola (Dahkki), Elizabeth Shiferaw (Dahkki), Vikram Dev (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Adis, Springer Healthcare, 2023-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Background Brexanolone is currently the only medication approved by the US FDA for the treatment of postpartum depression (PPD) in patients ≥15 years. Brexanolone is available commercially only through a restricted program (ZULRESSO® Risk Evaluation and Mitigation Strategy; REMS) due to ris...